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PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-
PET/CT, performed within two weeks of starting erlotinib therapy can predict
tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in
patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients.
PATIENTS AND METHODS: Three [¹⁸F]FDG-PET/CT scans were acquired in 12
patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late
PET) of erlotinib therapy. Conventional evaluation, including at least chest CT
(baseline versus after 8 weeks of treatment), was performed according to RECIST
1.1 criteria. Change in [¹⁸F]FDG uptake was compared with conventional response,
progression-free survival (PFS), and overall survival (OS).
RESULTS: By using ROC analysis, the Area Under the Curve for prediction of
metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to
1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake
Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive
disease; 4 with true non-progressive disease; 1 with false progressive disease).
Non-progressive disease after 8 weeks of treatment according to RECIST 1.1
criteria was significantly more frequent in patients classified mNP (P = 0.01,
Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04
to 0.59; P<0.01) and OS (HR = 0.34; 95% CI, 0.06 to 0.84; P = 0.03). Late PET
analysis provided concordant results.
CONCLUSION: Morphologic response, PFS and OS survival in non-small cell lung
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